Mara McDermott, Rachel Stauffer, and John Warren co-author a report on CMS’s notice of proposed rulemaking, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses,” which includes provisions that aim to reduce overall drug spending by giving Medicare Advantage and Part D plans additional tools to control use of high-cost drugs and by addressing cost shifting across programs.
On November 26, CMS released a notice of proposed rulemaking, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses,” which includes provisions that aim to reduce overall drug spending by giving Medicare Advantage and Part D plans additional tools to control use of high-cost drugs and by addressing cost shifting across programs. This On the Subject takes a closer look at three specific proposals from the most recent Proposed Rule, provides historical context for these developments, and offers insights into what is to come in the policy space for prescription drug pricing.
